Suzhou Xinmaide

Founded in 2016, SINGMED specializes in the design, research and development, and manufacturing of advanced drug delivery devices. The company focuses on creating drug-device combination products, particularly Dry Powder Inhalers (DPI), which are widely used for treating asthma and chronic obstructive pulmonary disease (COPD). DPIs offer several advantages, including portability, ease of use, quick administration, and minimal throat irritation, making them a preferred choice for many patients.

SINGMED serves a diverse client base, including pharmaceutical companies and healthcare providers, operating primarily in the medical device and pharmaceutical markets. The company's business model revolves around the development and sale of its proprietary drug delivery devices, as well as partnerships and collaborations with other pharmaceutical firms to create combination products. Revenue is generated through the sale of these devices and products, as well as through licensing agreements and royalties.

SINGMED's commitment to innovation and quality is evident in its continuous investment in research and development, as well as its recent expansion with the completion of the Singmed Changshu Production Base. This new facility marks a significant milestone in the company's growth and underscores its dedication to advancing medical technology.

Keywords: drug delivery devices, asthma treatment, COPD, Dry Powder Inhaler, pharmaceutical partnerships, medical device manufacturing, combination products, R&D, Singmed Changshu Production Base, healthcare innovation.